# T-cell anergy

Source: https://onco.cc/terms/anergy/  
OnCo record `anergy` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A living T cell can remain less responsive after an antigen encounter. A weak test result alone does not establish anergy.

## Summary

Anergy is antigen-related reduced responsiveness that persists into a later controlled response test. In Jenkins and Schwartz's mouse and T-cell-clone experiments, chemically altered presenting cells induced reduced responsiveness to subsequent antigen stimulation with normal presenting cells. Macian and colleagues identified an NFAT-associated anergy gene programme in mechanistic experiments. These findings are model evidence, not a universal tumour-cell classifier.

Exhaustion is a distinct differentiation programme associated with persistent stimulation. Anergy, exhaustion, external suppression, absent antigen-specific cells and assay failure are different possible explanations for a low response. Low interleukin-2 alone leaves the mechanism unresolved. Check specificity, viable-cell recovery, stimulus controls, responsive comparators and response history; measure division and cytokine responses under matched conditions. Laboratory rescue does not establish tumour recognition, safe killing or clinical benefit.

## Fields

- Kind: Term
- Last checked: 2026-11-09

## Notes

- Anergy is persistent reduced antigen-driven responsiveness after a defined antigen encounter, assessed with a suitable later challenge. It is not simply resting, a naive identity, missing support at one encounter or failure to divide now. Altered-presenting-cell induction followed by normal-presenting-cell retesting in mouse clones supports this distinction.
- In defined mechanistic experiments, unbalanced calcium signalling and NFAT without cooperative AP-1 promoted an anergy-associated gene programme. Reduced IL-2, a response-supporting cytokine, can accompany anergy. Signal strength, inhibitory context and experimental definition matter; inadequate costimulation is an example rather than a universal diagnosis.
- Low IL-2 or a negative ELISpot response alone does not establish anergy. Confirm antigen-specific cells, viable-cell recovery, matched stimulus and responsive comparators, response history and relevant pathway perturbations. Report dividing-cell fractions or cytokine concentration with assay units and conditions. Missing recognition, damaged preparations, suppression or exhaustion remain alternatives.
- Anergy can contribute to tolerance of mature immune cells. Protective restraint and tumour immune escape can overlap; changing a laboratory response does not establish restored specificity, tumour access, safe killing or clinical benefit.
- Anergy and exhaustion are distinct programmes, not compulsory successive stages or interchangeable labels for dysfunction. Dysfunction is a broader description that may also include senescence, external suppression and missing recognition. Classic clonal anergy often limits growth and IL-2 while retaining effector functions and can respond to added IL-2; adaptive tolerance has broader deficits and can reverse after antigen removal. These distinctions come from model and review evidence, not clinical cutoffs.
- Fictional independent populations A and B share verified specificity and suitable later stimulation. A has altered initial support followed by a controlled persistent defect; B has persistent stimulation with several functional deficits and compatible programme evidence. These support anergy-compatible and exhaustion-compatible explanations respectively. C with only low IL-2 remains unassigned. Viability, specificity and positive controls are necessary; no one control establishes state and no A-to-B transition or checkpoint-rescue prediction follows.
- Source scope: teaching synthesis checked against the cited abstracts and specified accessible primary text on 9 November 2026; fictional examples are not clinical observations or treatment-selection rules.

## Sources

- Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo.: https://pubmed.ncbi.nlm.nih.gov/3029267/
- Transcriptional mechanisms underlying lymphocyte tolerance.: https://pubmed.ncbi.nlm.nih.gov/12086671/
- Molecular signature of CD8+ T cell exhaustion during chronic viral infection.: https://pubmed.ncbi.nlm.nih.gov/17950003/
- Review (PubMed 12471050): https://pubmed.ncbi.nlm.nih.gov/12471050/
- Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.: https://pubmed.ncbi.nlm.nih.gov/7636184/
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.: https://pubmed.ncbi.nlm.nih.gov/30778252/

## Connected records

- terms: [T cell](https://onco.cc/terms/t-cell/)

---
JSON: https://onco.cc/api/v1/entities/anergy.json